Risk for respiratory complications in patients with type 2 diabetes not increased with use of GLP1 receptor agonists.
Endocrine Disorders
— DRUG MONOGRAPHS BY SUBSECTION —
News and Features
Strong recommendation given for addition of SGLT-2 or GLP-1 agonist to metformin and lifestyle modifications.
The shortage is expected to continue at least through the second quarter of 2024.
TempMonitor is able to provide a visual indicator when a medication has been exposed to unacceptable temperature levels.
No increase in aspiration or subsequent pneumonia seen among patients undergoing surgical procedures
Larger reductions seen in heart failure-related symptoms and physical limitations for patients with HFpEF, type 2 diabetes
Each SD increment in social determinants of health score linked to increased odds of diabetes, high BP, insufficient physical activity.
The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.
Caps are associated with reduction in insulin costs, mainly driven by patients enrolled in health savings accounts
Products are expected to be out of stock at wholesalers and pharmacies through the beginning of April
Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.
The discontinuation of these products is unrelated to any product quality, safety, or efficacy issues.
Second study shows low rate of SGLT2i prescribing even among patients with indications for therapy
The randomized, placebo-controlled PATHFNDR-2 study included 111 patients with acromegaly who had elevated IGF-1 levels and were treatment naïve.
The twiist AID system is designed to directly measure the volume and flow of insulin with every micro-dose, and address an individual’s dosing needs.
Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved.
Real-world data support the anemia reduction found in post hoc analyses of the CREDENCE and DAPA-CKD trials.
The Dexcom Stelo Glucose Biosensor System is an integral CGM intended for individuals 18 years of age and older with or without diabetes who are not on insulin.
The randomized, double-blind, parallel-group, placebo-controlled FLOW trial compared the effects of semaglutide 1mg, a GLP-1 receptor agonist, to placebo as an adjunct to standard of care on kidney outcomes.
‘Qualified health claim’ does not meet the more rigorous ‘significant scientific agreement’ standard.
- Loading...
